e-BioMatrix 6 Month DAPT France

Launched by BIOSENSORS EUROPE SA · Mar 5, 2018

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • "Real world, all comer" patients
• • 1. Age ≥18 years;
• • 2. Patients that need a treatment with a BioMatrix Flex™ drug- eluting stent or a BioMatrix NeoFlex™drug-eluting stent;
• • 3. Presence of one or more coronary artery stenoses in a native coronary artery from 2.25 to 4.0 mm in diameter that can be covered with one or multiple stents;
• • 4. No limitation on the number of treated lesions, vessels, and lesion length, within the limits of social security reimbursements;
• • 5. Patient with DAPT indication after PCI.
• Exclusion Criteria:
• • 1. Inability to provide informed consent;
• • 2. Patients needing additional stent NOT of the BioMatrix Flex™ or NeoFlex™ types;
• • 3. Patients receiving next to the BioMatrix Flex™ or BioMatrix NeoFlex™ also other coronary vascular interventions, for example, balloon dilation;
• • 4. Pregnant or planning to become pregnant patient;
• • 5. DES and BMS implantation less than 6 months before screening;